Pharmacogenomic Testing for Medication ManagementRADAR-PGXNCT02738047
Reduction of Adverse Drug Events and Readmissions
An observational study of Pharmacogenomic Testing for Medication Management, run by ClinLogic LLC at 1 site in United States.
Trial summary
Pharmocogenomic test assessment in the medication regimen and disease management for patients under drugs known with genetic variation. Read more about this study
- Who is it for?
- Ages 25 years and olderHealthy volunteers can take part
- Conditions the study is for
- Pharmacogenomic Testing for Medication Management
- How many people
- 280,000 participants
- Where
- 1 siteUnited States
- Study dates
- 15 Mar 2023to 15 Dec 2030
- How long will I take part?
- 120 Days
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients who are under treatment with several drugs with any of the sequences of biochemical reactions, catalyzed by enzymes, known to be influenced by genetic variation in a patient population.
Who may be able to join
- Patients may be included in the Study if they meet all of the following inclusion criteria:
- Male or female patients of 25 years of age or older who are able to give their written Informed Consent to participate in a Clinical Study based on voluntary agreement with a thorough explanation of the patient's participation will be provided to them.
- Patient underwent PGx testing for alleles appropriate to the target drugs within the prior 120 days ("index PGx test assessment");
- Patient was receiving at least one medication known to be associated with allelic variation at the time of the ("index PGx test assessment"), including over-the- counter medications;
- Patient has a history of at least one TDAE over the 24-month period preceding the PGx test assessment, or has experienced inadequate efficacy from a target drug.
Who cannot join
- Patients will be excluded from the Study if any of the following criteria apply:
- Patient is currently hospitalized;
- Patient's medical and medication history is unavailable over the 120-day period preceding the PGx test assessment;
- Patient is unable to provide an accurate history due to mental Incapacity;
- Patient is known to have undergone prior PGx testing for genes specific to the target drug(s), exclusive of the PGx test relating to this Study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
MD@Home
York, Pennsylvania, 17402
Marv Inscore, 717-840-8686
About this study
Official title: Pharmacogenomic Test Assessment for Medication Management in the Advancement of Medicine
Pharmocogenomic test assessment in the medication regimen and disease management for patients under drugs known with genetic variation.
Read the detailed description
Pharmocogenomic. A multicenter, observational study to evaluate the use of a Pharmocogenomic test assessment in the medication regimen and disease management for patients under drugs known to be influenced by genetic variation.
What is being measured
The primary outcome is the main question the study is designed to answer.
Radar, Pharmocogenomic
The primary endpoint of the study is the binary occurrence of meaningful change in drug regimen, defined in each patient when:
- A genotype known to affect a drug the patient is taking is identified, *and*
- The patient's treating physician makes at least one target drug regimen change, dose, substitution, or discontinuation.
Change in drug dose, substitution, or discontinuation among patients with an identified genotype known to affect a drug the patient is taking as directed. This will be assessed by a quantitative survey.
Measured: The period of enrollment is anticipated to be 36 months with a 120- day follow-up period, for total study duration of approximately 40 months from first patient enrolled to completion of follow-up on the last patient in.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Apr 2016 (estimated)
- Study start15 Mar 2023
- Primary completion1 Mar 2029 (estimated)
- Study completion15 Dec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pharmacogenomic Testing for Medication ManagementStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Other
- Enrolment
- 280,000 participants (estimated)
- Target duration
- 120 Days
Sponsor and investigators
- Lead sponsor
- ClinLogic LLC
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Haleh Farzanmehr, MD, Principal investigator, GXLHaleh Farzanmehr, MD, Study director, GXL
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02738047
- Sponsor's protocol ID
- 10202016
- Acronym
- RADAR-PGX
- Status last verified
- Oct 2026
- First submitted
- 28 Mar 2016
- Last updated
- 23 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 23 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pharmacogenomic Test Assessment for Medication Management in the Advancement of Medicine
- ClinicalTrials.gov ID
- NCT02738047
- Acronym / sponsor ID
- RADAR-PGX / 10202016
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 280,000 participants (estimated)
- Lead sponsor
- ClinLogic LLCIndustry (pharma, biotech, devices)
- Study start
- 15 Mar 2023 (actual)
- Primary completion
- 1 Mar 2029 (estimated)
- Study completion
- 15 Dec 2030 (estimated)
- First posted
- 14 Apr 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Pharmocogenomic test assessment in the medication regimen and disease management for patients under drugs known with genetic variation.
Detailed description
Pharmocogenomic. A multicenter, observational study to evaluate the use of a Pharmocogenomic test assessment in the medication regimen and disease management for patients under drugs known to be influenced by genetic variation.
Study design
- Observational model
- Other
- Time perspective
- Other
- Target follow-up
- 120 Days
Who may qualify
- Ages
- 25 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Patients who are under treatment with several drugs with any of the sequences of biochemical reactions, catalyzed by enzymes, known to be influenced by genetic variation in a patient population.
Key inclusion criteria (5 listed)
- Patients may be included in the Study if they meet all of the following inclusion criteria:
- Male or female patients of 25 years of age or older who are able to give their written Informed Consent to participate in a Clinical Study based on voluntary agreement with a thorough explanation of the patient's participation will be provided to them.
- Patient underwent PGx testing for alleles appropriate to the target drugs within the prior 120 days ("index PGx test assessment");
- Patient was receiving at least one medication known to be associated with allelic variation at the time of the ("index PGx test assessment"), including over-the- counter medications;
- Patient has a history of at least one TDAE over the 24-month period preceding the PGx test assessment, or has experienced inadequate efficacy from a target drug.
Key exclusion criteria (5 listed)
- Patient is currently hospitalized;
- Patient's medical and medication history is unavailable over the 120-day period preceding the PGx test assessment;
- Patient is unable to provide an accurate history due to mental Incapacity;
- Patient is known to have undergone prior PGx testing for genes specific to the target drug(s), exclusive of the PGx test relating to this Study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Radar, Pharmocogenomic
Time frame: The period of enrollment is anticipated to be 36 months with a 120- day follow-up period, for total study duration of approximately 40 months from first patient enrolled to completion of follow-up on the last patient in.
The primary endpoint of the study is the binary occurrence of meaningful change in drug regimen, defined in each patient when: 1. A genotype known to affect a drug the patient is taking is identified, *and* 2. The patient's treating physician makes at least one target drug regimen change, dose, substitution, or discontinuation. Change in drug dose, substitution, or discontinuation among patients with an identified genotype known to affect a drug the patient is taking as directed. This will be assessed by a quantitative survey.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Oct 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Pharmacogenomic Testing for Medication Management
Not yet recruitingObservational study
Individual Risk Profiles for Adverse Drug Reactions in Geriatric Patients
Polypharmacy, Pharmacogenetics
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Haleh Farzanmehr, MD principal investigator
GXL
Haleh Farzanmehr, MD study director
GXL
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pharmacogenomic Testing for Medication Management, run by ClinLogic LLC at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 23 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Diana Messir (239-908-0412, Diana@integritycro.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Radar, Pharmocogenomic (time frame: The period of enrollment is anticipated to be 36 months with a 120- day follow-up period, for total study duration of approximately 40 months from first patient enrolled to completion of follow-up on the last patient in.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Oct 2026.